The differential diagnosis between reactive mesothelial proliferation, malignant mesothelioma (MM), and metastatic adenocarcinoma can be challenging. This pleural fluid specimen is relatively cellular, with one predominant population of cells. These cells have abundant dense perinuclear cytoplasm, centrally located nuclei, prominent nucleoli, and relatively normal nuclear-cytoplasmic (N/C) ratio, which suggest that these cells are mesothelial cells. Many large clusters are present, with scalloped, flower-like outlines. In both smear sample and cell block, atypical cells with binucleated or multinucleated cells are commonly seen. Therefore, MM is on the top of the differential diagnoses.
Melanoma is less likely the cause, in this case. MM cells seen in pleural effusion specimen usually have abundant cytoplasm with prominent nucleoli that can mimic mesothelial cells. However, the melanoma cells usually do not form cell clusters, and they often contain pigment and intranuclear pseudoinclusions. However, as the patient has a reported history of melanoma, it should not be immediately excluded.
Lymphoma is not in the differential diagnosis. Unlike lymphoid neoplasms, the cells in this patient's sample are cohesive with abundant cytoplasm and epithelioid morphology.
Follow-up of present case
Computerized tomography scan of the chest with intravenous contrast after the patient underwent thoracentesis revealed a 7 mm smooth nodule abutting the anterior pleural space of the right middle lobe. Furthermore, a 3 mm nodule is in the anterior right upper lobe. Subsequently, the patient underwent right pleural biopsy through video-assisted thoracoscopic (VAT) surgery. The thoracic cavity was inspected, and multiple plaques were noted over the pleura, as well as some studding over the lung and diaphragm. 
ADDITIONAL QUIZ QUESTIONS

ANSWERS TO ADDITIONAL QUESTIONS
Q1 (c); Q2 (c); Q3 (a).
Q1 (c) -Calretinin, WT-1, Ber-Ep4, and MOC-31: The correct answer is C. In many cases, morphology alone is not sufficient to make a definitive diagnosis. IHC stains are very useful in differentiating metastatic adenocarcinoma from MM and establishing the primary origin of a metastatic adenocarcinoma.
IHC panels should include at least two markers for metastatic adenocarcinoma and two for MM. [1] Calretinin and WT-1 are considered as the first front-line mesothelial markers. Other mesothelial markers include D2-40 (podoplanin antibody, mesothelin, CK5/6, HBME-1, and thrombomodulin). [2] [3] [4] The diagnostic markers for adenocarcinoma include CEA, Ber-Ep4, BG-8, B72.3, and MOC-31. [3, 5] Q2 (c) -EMA and GLUT-1 negativity: The correct answer is C. The diagnosis of MM sometimes is challenging as reactive mesothelium can resemble neoplastic mesothelium. Generally speaking the presence of numerous large cell clusters (>50 cells) with scalloped border is characteristic of MM. [3] Cell-to-cell engulfment, cytomegaly, macronucleoli, and marked atypia are additional features which favor MM.
IHC markers might be useful in distinguishing between MM and benign mesothelial proliferation. EMA, p53, insulin-like growth factor messenger RNA-binding protein 3 (IMP3), and GLUT-1 appear to be preferentially expressed in neoplastic mesothelium. [6] [7] [8] EMA seems to be See next pages for brief review of the topic. http://www.cytojournal.com/content/14/1/18 the best marker in this purpose when E29 clone is used in studies. [8, 9] Immunolabeling for desmin appears to be in favor of reactive mesothelial cells. [6] However, IHC results should be interpreted with caution since the specificity and positive predictive values may not be high enough for the definitive diagnosis of MM.
Recently, mutations of BAP1 gene were reported in hereditary and sporadic MM. [10] BAP1 protein is frequently lost in MM and is commonly associated with homozygous BAP1 deletion. Loss of BAP1 IHC staining points to a diagnosis of MM. [11] Q3 (a) -BRAF V660E: The correct answer is A. As BRAF v660E mutations are associated with melanoma, colorectal cancers, and other malignancies but not MM.
Many genetic changes have been detected in MM. The most common genetic alterations include inactivation of the tumor suppressor gene NF2, homozygous deletion of the 9p21 locus, and loss of BAP1. [12] The 9p21 locus encompasses p16INK4A (also called CDKN2A), p14ARF, MTAP, and p15INK4. [13] 
Follow-up of present case (if any)
Evaluation of the cytology specimens, which contained numerous clusters of mild to moderately atypical epithelioid cells in cohesive groups of variable sizes, was suspicious for a malignant process. Biopsy from the pleura demonstrated chronic fibrinous pleuritis with an atypical mesothelial proliferation in a solid and glandular/ cribriform pattern with superficial invasive growth pattern. Tumor cells showed loss of BAP-1 staining [ Figure 2 ]. IHC studies performed on the cell block, and the biopsy specimen showed that mesothelial marker (calretinin) was strongly positive in the atypical cell groups. Other markers (CK 7, BerEp4, napsin A, TTF-1, PAX-8, and 
BRIEF REVIEW OF THE TOPIC
Role of cytology MM is a rare primary serosal malignancy with an incidence 1-6/100,000 and accounts for <2% of malignant pleural effusion. [14, 15] In malignant pleural effusion, metastatic tumors are far more common than primary MM. [14] Most cases of MM are seen in male patients between the ages of 50 and 70 years and related to asbestos exposure. [16] MM patients often initially present with pleural effusion. The classic clinical scenario also includes chest pain, weight loss, shortness of breath, and persistent pleural effusion. Thoracocentesis is both therapeutic/palliative as well as a useful diagnostic procedure. The cytological examination of the pleural fluid is one of the primary diagnostic tools in these patients. The specificity of MM diagnosis is high when cytopathologic features are combined with ancillary tests. [3, 17] Some groups propose that cytology alone is a reliable diagnostic tool when interpreted by "experienced cytopathologists" and combined with IHC characterization. [18] In addition, the presence of malignant mesothelial proliferation in pleural fluid may be sufficient for diagnosis in some patients when correlated with the clinical features and radiology studies, and when biopsy is contraindicated. [19] However, it should be noted that some guidelines indicate that the definitive diagnosis requires the demonstration of invasion by neoplastic mesothelium into stroma or subpleural fat either by histological examination or by imaging studies. [12, 19] One major pitfall in attempting cytology-based effusion diagnosis of MM is relatively low sensitivity, ranging from 32% to 76%. [2, 3, 17] To achieve a correct cytologic diagnosis, it is recommended that a minimum of 100 mL of effusion fluid is submitted for cytology. [16] Application of IHC and molecular techniques greatly improves diagnostic accuracy. In addition, only the epithelioid and mixed types of MM exfoliate malignant cells, while sarcomatoid and desmoplastic types are not usually detected in pleural fluid.
Focused differential diagnosis
In pleural fluid, the major differential diagnoses include MM, metastatic adenocarcinoma, and reactive mesothelial proliferation.
Malignant mesothelioma versus metastatic adenocarcinoma
In pleural fluid, numerous large clusters with prominent atypical cells and/or conspicuous atypical cells suggest malignant effusions. Metastatic adenocarcinoma is more common than primary MM.
• The key feature for metastatic adenocarcinoma is detecting a foreign "second" population of cells in the pleural effusion, which are morphologically malignant • Mesothelial markers: Calretinin, WT-1, D2-40, CK5/6, HBME-1, and thrombomodulin [2] [3] [4] • Markers for adenocarcinoma include CEA, Ber-Ep4, BG-8, B72.3, and MOC-31 [3, 5] • Depending on the differential diagnosis, additional markers can be added to the diagnostic panel [12, 20] • TTF-1 and Napsin A are particularly useful for lung primary carcinoma • CDX2 and CD20 can help distinguish gastrointestinal adenocarcinoma • PAX-8 and ER can suggest gynecologic primary site • Mammaglobin, GATA-3, and GCDFP-1 are compatible with metastatic breast carcinoma.
• The immunocytochemical evaluation of effusion fluids can be facilitated by a strategy, "subtractive coordinate immunoreactivity pattern"
• The cell blocks of the effusion fluids are serially sectioned, oriented identically, and labeled sequentially. Therefore, the same group of cells can be feasibly identified and evaluated for variable markers. This approach greatly assists the confirmation of the "second foreign population." [21] Malignant mesothelioma versus reactive mesothelial proliferation
• The presence of large cell clusters (>50 cells per group) is probably the most useful clue for MM. On the contrary, benign mesothelial cell proliferation tends to disperse as isolated cells, forming monolayer cell aggregates or small clusters • Malignant mesothelial cells tend to be larger than reactive cells with macronucleoli and marked cytologic atypia. Reactive mesothelial cells can be very atypical with prominent nucleoli and morphologically indistinguishable • Ancillary tests could be helpful
• IHC markers which favor MM when positive: EMA, p53, IMP3, and GLUT-1 and when negative: BAP1 [6] [7] [8] • IHC markers which favor reactive mesothelial cells when positive: Desmin [6] • Detection of CDKN2A (9p21) deletion through FISH study. In the appropriate context, homozygous deletion of CDKN2A can support the definitive diagnosis of MM.
Molecular markers in malignant mesothelioma
One of the most common genetic mutations of MM is the homozygous deletion of the 9p21 locus, harboring p16INK4A (also called CDKN2A), p14ARF, MTAP, and p15INK4. The homozygous deletion of p16/CDKN2A should not be present in reactive mesothelial proliferation and is present in up to 80% of MM. [22] [23] [24] [25] Therefore, detection of homozygous CDKN2A deletion can be a useful approach to detect MM. Studies have shown the sensitivity of p16 FISH lies between 58% and 79%, with almost 100% specificity, superior to IHC marker GLUT-1. [2, 22, 25] It should be noted that the application of FISH is to confirm the malignancy, while IHC stain studies are necessary to identify the mesothelial origin. Homozygous deletion of the P16 gene is also a significant independent adverse prognostic factor. [26] The BAP1 gene is a tumor suppressor gene located on chromosome 3p21, encoding a deubiquitinating enzyme, which regulates cell cycle, cellular differentiation, transcription, and DNA damage response. [27] Recently, mutations of BAP1 gene were reported in hereditary and sporadic MM, with 40%-60% in epithelioid MM and <20% in sarcomatoid MMs. [10, 16, 28] More studies have shown that germline BAP1 mutations are associated with a novel cancer syndrome characterized by MM, uveal melanoma, cutaneous melanoma and melanocytic BAP1-mutated atypical intradermal tumors, and possibly by other cancers. [29] BAP1 protein loss associated with homozygous BAP1 deletion is only seen in MMs. [30] BAP1 IHC (IHC) has been reported as a reliable marker to distinguish MM from reactive mesothelial proliferations. Studies have shown that loss of BAP1 IHC staining is highly specific (up to 100%) in distinguishing MM over benign mesothelial proliferation, with overall sensitivity of more than 50%. [11, 24, 31, 32] Patients having MM with the presence of BAP1 mutation have a better prognosis. [33] The finding of homozygous deletion of p16 by FISH or loss of BAP1 by IHC can be very useful diagnostic tools in differentiating benign mesothelial proliferation from MM. A drawback of p16 FISH and BAP1 IHC staining is that they have relatively low sensitivity and cannot be used to exclude the diagnosis. Co-testing with both the above-mentioned ancillary techniques improves the limited sensitivity of the individual tests.
The differentiation between MM and reactive mesothelial proliferation is diagnostically challenging due to their overlapping cytological features. FISH for p16/CDKN2A deletion and loss of BAP1 by IHC are useful tests for confirming the diagnosis of MM.
